John F. Seymour
Peter MacCallum Cancer Centre
781 Papers
5.1K Citations
John F. Seymour is an academic researcher from Peter MacCallum Cancer Centre. The author has contributed to research in topics: Medicine & Rituximab. The author has an hindex of 96, co-authored 706 publications. Previous affiliations of John F. Seymour include Royal Children's Hospital & St. Vincent's Health System.
Chat about Author
Papers
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Henry Miles Prince,Danny Rischin,G. C. Toner,John F. Seymour,D. Blakey,P. Gates,S Eerhard,P Chapple,Michael A. Quinn,M Brettell,Surender Juneja,Max Wolf,EH Januszewicz,G Richardson,J. Scarlett,P. Briggs +15 more
TL;DR: This phase I study found the optimal dosages of a novel repetitive high-dose therapy regimen for patients with metastatic breast cancer to be cyclophosphamide, thiotepa and docetaxel, supported by peripheral blood progenitor cells (PBPC) and filgrastim.
12
Insights into the development of a nurse-led survivorship care intervention for long-term survivors of Hodgkin lymphoma
Priscilla Gates,John F. Seymour,Mei Krishnasamy +2 more
- 01 Jun 2012
TL;DR: The rationale and key design issues behind the development of the nurse-led intervention for Hodgkin lymphoma survivors, some preliminary indication of the benefit of the intervention from participants' perspective and a phase 1, quasi-experimental study are outlined.
12
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
William Townsend,Wolfgang Hiddemann,Christian Buske,Guillaume Cartron,David Cunningham,Martin J. S. Dyer,John G. Gribben,Elizabeth J. Phillips,Martin Dreyling,John F. Seymour,Andrew Grigg,Judith Trotman,Tong Yu Lin,Xiaonan Hong,D. Kingbiel,Tina Nielsen,Andrea Knapp,Michael Herold,Robert Marcus +18 more
TL;DR: The phase III GALLIUM trial as discussed by the authors evaluated the safety and efficacy of obinutuzumab-based versus rituximabbased immunochemotherapy in patients with previously untreated follicular lymphoma or marginal zone lymphoma (MZL).
12
Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia.
Constantine S. Tam,Constantine S. Tam,Thomas E. Kimber,Thomas E. Kimber,John F. Seymour,John F. Seymour +5 more
TL;DR: Lehmann, S., Gabriel, S.B., Moran, J.S., Sullivan, P.F., Sklar, P., Gronberg, H., Hultman, C.M., McCarthy, M.L. & Kristensen, V.N. (2015) Leukemia-associated somatic mutations drive distinct patterns of agerelated clonal hemopoiesis.
12
The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study
John F. Seymour,Matthew S. Davids,Mary Ann Anderson,Thomas J. Kipps,William G. Wierda,John M. Pagel,Brad S. Kahl,Thomas P. Miller,David E. Darden,Cathy E. Nolan,Lori A. Gressick,Hao Xiong,David C.S. Huang,Brenda J. Chyla,Todd A. Busman,Alison M. Graham,Elisa Cerri,Sari H. Enschede,Rod A. Humerickhouse,Andrew W. Roberts +19 more
TL;DR: ABT-199 shows single agent anti-tumor activity in patients with NHL; particularly in MCL and DLBCL; and no dose-limiting toxicities have been identified to date.
12